Systemic Drug Delivery

Mucosal delivery provides non-invasive, rapid absorption and onset of action without unwanted hepatic metabolism of the drug. The major disadvantage of most nasal drug delivery devices is they only apply medication to the closest one-third of the nasal cavity, thus limiting drug absorption for treatment of systemic diseases. CPD's optimal mucosal saturation and depth of drug penetration will lead to improved systemic treatment of conditions such as osteoporosis and migraine headaches. However, good drug candidates for intranasal delivery are any that undergo extensive first-pass metabolism, display erratic absorption, or require quick therapeutic onset.

  Home | Nasal Drug Delivery | Technology | Clinical Studies | Devices | Investors | News & Events | About Kurve | Contact

Copyright 2017, Kurve Technology, Inc. All Rights Reserved | Site Map
Technology Marketing